Allogenic stem cell transplantation (allo-SCT) represents the only curative option for several hematological malignancies. Due to a delayed and dysfunctional immunological recovery infectious complications and residual tumor cells following allo-SCT are still major causes of failure of this procedure. Here we discuss the most common infectious complications of allo-SCT and describe current and future strategies to prophylaxe or treat these complications using novel immunotherapeutic strategies.
INTRODUCTION
Allogeneic hematopoietic stem cell transplantation (allo-SCT) represents the only curative option for several hematological malignancies. Although several improvements in conditioning regimens and SCT procedures (especially in vivo/ex vivo T-cell depletion) allow to achieve a fast and long-lasting regeneration of hematopoiesis, patients are still suffering from major complications due to a delayed and dysfunctional immunological recovery. Disease relapse and life-threatening infections with multiple pathogens (for example, CMV, EBV, adenovirus (ADV), Aspergillus spp., Candida spp. and so on) severely affect the ultimate outcome of SCT. Disease status, previous treatment, patient age and the degree of donor/patient mismatches are critical variables influencing the relative risks of relapse and infections. A major strategy to deal with viral and in the future also fungal infection is the clinical application of T-cell subsets directed against multiple pathogens in a patient-tailored approach, able to boost and shape the novel donor-derived immune system toward proper antigens and ultimately improve the clinical outcome.
Clinical application needs to include central memory T cells, T HELPER cells and probably also effector memory T cells. This goal, which represents a major progress for patients with hematological malignancies, will be pursued through the development of innovative strategies of isolation, expansion and manipulation of donor T-lymphocyte subpopulations. Adoptive transfer of T cells directed against single viral pathogens has been effective in small phase I/II studies but often therapeutic efficacy was limited not only owing to the lack of persistence and migration of the transferred donor T cells to the site of infection, but also by additional infections not targeted by the transferred T cells.
Therefore the aim of adoptive T-cell therapy is the generation of polyclonal T-cell populations against multiple pathogens, not only by adding T cells directed against different infectious pathogens, but also by the controlled coordination of a variety of T-cell populations and T-cell responses. To favor long-lasting clinical responses new T-cell selection and manipulation procedures that favor the generation of antigen-specific central memory and memory stem T cells, a recently discovered T-cell subset characterized by a high degree of plasticity, expansion potential and self-renewal capacities has to be pursued.
Suitable combination of antigens/T-cell epitopes will allow for optimal stimulation and selection of multiple pathogen-specific T cell lines and a characterization of pathogen specificity and alloreactivity for safety and quality control of the generated T cell lines.
Furthermore, for the high-risk patients who are seropositive and receive a transplant from a seronegative donor, T-cell priming or redirection of donor T cells have to be used as well as the transfer of antigen-specific cells from seropositive third party donors.
VIRAL INFECTIONS POST TRANSPLANT
Allo-SCT can cure patients with several hematological malignancies but exposes patients to periods of marked immunosuppression, during which infections, especially viral and fungal infections, can cause morbidity and mortality. CMV reactivation/disease has a major negative impact on the outcome of SCT.
1,2 Inspite of novel anti-CMV drugs (CMX001 and letermovir) with promising activity and good safety profile, 3 CMV infection remains a life-threatening complication and a major cause of infection-related mortality in recipients of an allo-SCT, especially in patients undergoing cord blood or haploidentical SCT as well as patients with severe acute or extensive chronic GvHD.
In addition, ADV infections have been increasingly described in these patients with an incidence up to 29%, again with patients undergoing a stem cell transplant from an alternative donor being the patient cohort at a highest risk for ADV infection and disease.
EBV reactivations post SCT can induce life-threatening posttransplant lymphoproliferative disease. Current data reveal that serotherapy with anti-thymocyte globulin or Campath as well as the occurrence of severe acute GvHD and also SCT from an alternative donor or a mismatched related or unrelated donor is associated with an increased risk for an EBV-related lymphoproliferative disorder. been expressed. 6 Several groups have reported potential protocols, [7] [8] [9] [10] but only very limited clinical trial activity has been reported so far.
FUNGAL INFECTIONS
Invasive fungal infections are one of the major threats to patients undergoing allo-SCT. The incidence of invasive fungal infection depending on the geographic localization of the transplantation center as well as the percentage of patients belonging to high-risk group for invasive fungal infection can go beyond 15%. Yet diagnostic techniques are rather insensitive and not very reliable-leading to a vast overtreatment of patients-often as a prophylaxis-with drugs that are potentially toxic but definitely very expensive. Thus, large transplant centers spend easily 41 Mio € for diagnostic and therapeutic strategies to prevent and treat invasive fungal infection. In spite of these high costs, the outcome of invasive fungal infection, especially when lung and even more important the central nervous system is involved, is rather poor (mortality ranging from 30 to 80% depending on the underlying disease and the transplant modality as well as the occurrence of severe acute and chronic GvHD).
Thus, new diagnostic and treatment strategies for invasive fungal infection are highly warranted.
IMMUNOTHERAPY FOR FUNGAL INFECTIONS
Studies in mice and humans suggest the importance of the T-helper type 1 (Th1) response in conferring protection against invasive aspergillosis. Th1 interferon-gamma-secreting cells are believed to increase innate immune responses 9 against aspergillus by activating macrophages and neutrophils, and enhance antimicrobial activity of respiratory epithelial cells. Mice given neutralizing antibodies against Th2 cytokines to indirectly enhance Th1 cytokine production have increased protection against aspergillosis and Th1 cells obtained from mice previously immunized with aspergillus antigens were shown to protect from aspergillosis following adoptive transfer to otherwise susceptible mice. Patients undergoing allo-SCT are also at a high risk to develop invasive aspergillosis and we have shown that a low rate of T-cell proliferation when exposed to aspergillus antigens as well as a predominant aspergillus-specific Th2 response are associated with a worse outcome of invasive aspergillosis in patients who have undergone allo-SCT. 11 Several groups have established methods to select and expand aspergillus-specific T cells and a small clinical trial has shown promising activity and good safety of the transfer of in vitro stimulated and selected aspergillus-specific T-cell clones to patients with uncontrolled invasive aspergillosis following allo-SCT. 12 In addition, we and others have shown that also activated natural killer cells-which can be easily selected and enriched for-can mediate anti-aspergillus activity. [13] [14] [15] Data from our group have also demonstrated that isolated gamma-delta T cells can mediate anti-aspergillus activity.
11
Gamma-delta T lymphocytes can be highly enriched for under good manufacturing practice conditions using the Clinimacs device 16, 17 and also easily be activated and expanded in vivo by stimulation with aminobisphosphonates. 18 Thus, this cell population that also mediates antiviral and antitumor activity, 19, 20 but does not mediate alloreactivity will be a very attractive option to be used for adoptive immunotherapy for infection and tumor control post transplant.
IMMUNOTHERAPY FOR VIRAL INFECTIONS
Antigen-specific T cells against single pathogens (ADV, CMV and EBV) have been and are currently investigated by several groups with the aim of adoptive transfer directed against single antigens in viral infection, which can lead to reconstitution of antiviral immunity after SCT. [21] [22] [23] [24] So far, logistics have limited the application of cellular therapies and short-term in vivo persistence clearly interferes with the antiviral efficacy of transferred T cells. Recently, a long-lived human memory T-cell population has been described with relevance for adoptive T-cell transfer approaches. This subpopulation has an enhanced capacity for self-renewal and a multipotent ability to derive central memory, effector memory and effector T cells. These cells, specific to multiple viral and self-tumor antigens, were found within a CD45RO -, CCR7 + , CD45RA + , CD62L + , CD27 + , CD28 + and IL-7Rα + T-cell compartment characteristic of naive T cells. However, they expressed large amounts of CD95, IL-2Rβ, CXCR3 and LFA-1, and showed numerous functional attributes distinctive of memory cells. Compared with known memory populations, these lymphocytes had increased proliferative capacity and more efficiently reconstituted immunodeficient hosts and were recently termed memory stem T cells. 25 As T-cell responses can reconstitute even from a single T cell, repopulating capacities are of clinical significance for adoptive T-cell transfer approaches. 26 However, the starting population/phenotype for socalled 'giant T-cell clones' 27 is still not clear in humans. Adoptive T-cell transfer for CMV reactivation after SCT has been performed over decades with T cell lines generated by repetitive stimulation in vitro.
21,28
New strategies of T-cell selection using antigen-induced T-cell stimulation and isolation by cytokine capture assay, streptamer technology 29 or via increased expression of activation markers has been developed. 9, 10, 30 In a recent study, this approach has been successfully applied to patients with chemorefractory CMV infection and disease. 31 Adoptive transfer of antigen-specific T cells for EBV, ADV and CMV is now established at several centers in a clinical protocol with the required clinical, immunological, virological, technical and regulatory preconditions. 6, 30 Selective allodepletion may serve as an improved platform technology where GvHD-causing T cells are depleted from the stem cell allograft enabling the remaining T-cell repertoire to facilitate anti-infectious antimalignant properties in the presence of low or no immunosuppression. Various methods of allodepletion have been successfully established, some of which including CD25-immunotoxin-based allodepletion and TH9402-based photodepletion have been already transferred into the clinical setting. [32] [33] [34] [35] [36] International multicenter trials are recruiting. Until now 4100 patients after allo-SCT have been treated against single pathogens all over Europe with Ag-specific T cells. 37, 38 However, in vivo persistence of transferred T cells in the recipient remains a problem of T-cell transfer either due to inherent properties of the T-cell product or due to immunosuppressive drugs in the recipient. Especially, third-party T-cell transfer from HLA-partially matched donors has been shown safe and feasible 38, 39 but in vivo persistence of T cells is limited. In addition, the role of CD4 + T HELPER cells, which have been emphasized over many years for the efficacy of adoptive T-cell transfer, 9, 21, 24, 40, 41 still remains to be investigated.
SELECTION/GENERATION AND TRANSFER OF MULTIPATHOGEN-SPECIFIC T CELLS
In the past few years novel screening techniques have revealed multiple viral and fungal pathogens to emerge as major contributors to post-transplant morbidity and mortality, expanding from CMV, EBV, ADV) to HSV, BK virus and VZV, also including HHV-6 and several fungal pathogens, for example, Aspergillus spp., Candida spp., especially non-albicans Candida spp. and as an emergent problem also Mucor spp.
Thus, an urgent clinical demand for enriched multivirus and also multipathogen-specific T cells with reduced alloreactivity has been expressed. 6 Several groups have reported potential protocols, 7, 8, 10, 42 but only very limited clinical trial activity has been reported so far.
Broader implementation of multipathogen-specific T-cell therapy is restricted by the limited spectrum of immunodominant viral and fungal proteins and peptides defined and available that can be targeted in a single T cell line and the logistics of manufacture of these lines. One major problem anticipated in the generation of multipathogen-specific cell lines is the antigenic competition between high-and low-frequency T cells as well as T cells of high and low avidity. Competition for shared APCs may favor the generation of T cell lines dominated by responses to a single or only a few pathogens, thus limiting the coverage of pathogens provided by the T-cell product. In addition, often the manufacturing process used to generate these multipathogenspecific T-cell products is very complex and extremely labor and time consuming. Thus, we have established two new strategies to isolate mutlipathogen-specific T cell lines for the treatment of patients at risk for multiple viral and fungal infections post transplant.
We are evaluating the use of MHC multimers that reversibly bind to the TCR of antiviral and antifungal CD8+ and CD4+ T cells. Using these streptamers and peptide pools covering several of the immunodominat viral antigenic epitopes, we have been able to generate T cell lines at high purity. 29, 43 The technology can also be used to generate multivirus-specific T cell lines at high purity and with a good yield (unpublished results). An alternative technology developed in our labs is the selection of T cells directed against viral and fungal antigenic epitopes by stimulation with peptide mixes covering several relevant CMV-, EBV-, ADV-, Aspergillus fumigatus-and Candida albicans-specific T-cell epitopes followed by selection via the upregulated activation markers (for example, CD137, CD154 and so on). 9 For generation from multipathogen-specific T cells from a seronegative donor in vitro priming using professional APCs pulsed with the relevant peptides from immunodominant viral antigens in the presence of exogenous cytokines, especially IL7 and IL15 can be used. In addition, the depletion of regulatory T cells and the selection of the primed pathogen-specific T cells via surface expression of activation markers plus/without in vitro expansion have been shown to further increase the yield of multipathogen-specific T cells. 44 This approach has been applied with dendritic cells out of a minimum of 100 mL whole blood, but will require extensive T-cell expansion including CD3/28 beads for sufficient cell numbers (for clinical application plus T-cell assays).
Another strategy to generate multipathogen-specific T cells in case of a seronegative stem cell donor is to isolate these cells from a not completely HLA-matched third party donor. This strategy requires high purity and a predominant selection of T-cell populations with capacity of 'self-renewal'.
These approaches will have to be tested extensively in vitro for safety and efficacy.
One multicenter study has used banked third party virusspecific T cells to treat severe viral infections after hematopoietic SCT. 39 After preparation of a bank of 32 virus-specific T cell lines from individuals with common HLA polymorphisms with detectable T-cell responses to EBV, CMV or ADV, 50 patients with severe, therapy-refractory CMV, EBV or ADV infection after allo-SCT were treated with one of these T cell lines. More than 70% of patients who received multivirus-specific T cell lines from the bank third party donor T cells responded-independent of the treated viral infection (CMV, EBV and ADV). Only four responders had a recurrence or progression. The frequency of virus-specific T cells that circulated in the peripheral blood increased significantly post infusion, coincident with the decrease in viral load.
In patients who could be monitored for circulating T cells from the third party, donor persistence of the transferred T cells could be demonstrated up to 12 weeks.
Several hundreds of patients were treated successfully and with little toxicity with CMV-, EBV-and ADV-specific T cells for refractory virus infection following allo-SCT. In addition, isolation of multipathogen-specific T cells can be successfully achieved from the seropositive donors using novel selection devices. In some patients multipathogen-specific T cells also were successfully administered and showed antiviral activity and successful control of CMV, EBV and ADV infection.
